Targeted Nanotherapy andAdvanced Biosensing: A Novel Approach to Preventing and Treating Fibrodysplasia Ossificans Progressiva

Volume: 10 | Issue: 02 | Year 2024 | Subscription
International journal of Nanobiotechnology
Received Date: 09/04/2024
Acceptance Date: 10/01/2024
Published On: 2024-10-11
First Page:
Last Page:

Journal Menu

By: S. Anand

Professor, Department of Computer Science and Engineering Infant Jesus College of Engineering

Abstract

Fibrodysplasia ossificans progressiva (FOP) is an exceptionally rare and debilitating genetic disorder marked by the gradual transformation of soft tissues into bone, severely impairing movement and reducing lifespan. This review delves into the potential of cutting-edge nanotherapy and advanced biosensing technologies as novel strategies for both preventing and treating FOP. Nanotechnology holds promise for creating targeted drug delivery systems and real-time monitoring tools designed to precisely address the mutant ACVR1 gene, which is central to FOP pathology, and to correct the abnormal bone morphogenetic protein (BMP) signaling pathways involved in the disease.
Targeted nanotherapy involves engineering nanoparticles to deliver drugs directly to the mutated gene and modulate the signaling pathways that contribute to aberrant bone formation. By focusing on the specific genetic and molecular mechanisms underlying FOP, this approach aims to mitigate the progression of the disorder and enhance patient outcomes. Concurrently, advanced biosensing technologies offer the capability to monitor the disease in real time, providing critical insights into the efficacy of treatments and the status of disease progression.
This review encompasses a thorough examination of the current landscape of FOP research, elucidates the fundamental principles of targeted nanotherapy and biosensing, and explores their potential applications in managing FOP. We discuss relevant case studies, experimental results, and emerging trends in these fields, underscoring both the challenges and opportunities in combating this challenging condition. By integrating these innovative technologies, there is renewed hope for improving the quality of life for individuals with FOP and furthering our comprehension of this complex genetic disorder.

Keywords: Fibrodysplasia ossificans progressiva (FOP), targeted nanotherapy, advanced biosensing, ACVR1 gene, bone morphogenetic protein (BMP) signaling, nanotechnology, drug delivery, real-time monitoring, genetic disorders, personalized medicine

Loading

Citation:

How to cite this article: S. Anand, Targeted Nanotherapy andAdvanced Biosensing: A Novel Approach to Preventing and Treating Fibrodysplasia Ossificans Progressiva. International journal of Nanobiotechnology. 2024; 10(02): -p.

How to cite this URL: S. Anand, Targeted Nanotherapy andAdvanced Biosensing: A Novel Approach to Preventing and Treating Fibrodysplasia Ossificans Progressiva. International journal of Nanobiotechnology. 2024; 10(02): -p. Available from:https://journalspub.com/publication/targeted-nanotherapy-andadvanced-biosensing-a-novel-approach-to-preventing-and-treating-fibrodysplasia-ossificans-progressiva/

Refrences:

 

[1] Yang, Tie-Lin, et al. “A road map for understanding molecular and genetic determinants of osteoporosis.” Nature Reviews Endocrinology 16.2 (2020): 91-103

[2] Haupt, Julia, et al. “ACVR1 p. Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p. Q207D variant.” Human molecular genetics 23.20 (2014): 5364-5377.

[3] Tarannum, Mubin, and Juan L. Vivero-Escoto. “Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.” Advanced Drug Delivery Reviews 187 (2022): 114357.

[4] Galvin, Paul, et al. “Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications.” Cellular and Molecular Life Sciences 69 (2012): 389-404.

[5] Ganji, M.R., & Thakur, M.S. (2004). Microprocessor based biosensors for determination of toxins and pathogens in restricted areas of human intervention. In Proceedings of the International Conference on Artificial Intelligence, IC-AI’04 (Vol. 1, pp. 525-531).

[6] Eswaran, U et al., “Design and Analysis of High Sensitive Microcantilever Based Biosensor for CA 15-3 biomarker detection,” Journal of Applied Science and Computations, 2018, 682-698, ISSN: 1076-5131. DOI:16.10089.JASC.2018.V5I7.453459.0050021

[7] Galvin, Paul, et al. “Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications.” Cellular and Molecular Life Sciences 69 (2012): 389-404.

[8] Holzapfel, Boris Michael, et al. “How smart do biomaterials need to be? A translational science and clinical point of view.” Advanced drug delivery reviews 65.4 (2013): 581-603.

[9] Ferreira, Fátima José Mendes. Laponite-based nanogels for bone tissue regeneration: optimization and efficacy studies. MS thesis. Universidade da Madeira (Portugal), 2020.

[10] Hsiao, Edward C., et al. “Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP).” British journal of clinical pharmacology 85.6 (2019): 1199-1207.

[11] Cappato, Serena, et al. “The horizon of a therapy for rare genetic diseases: a “druggable” future for fibrodysplasia ossificans progressiva.” International journal of molecular sciences 19.4 (2018): 989.

[12] Murali, K., et.al.,(2024). Application of Sensors for Smart Farming. In A. Khang (Ed.), Agriculture and Aquaculture Applications of Biosensors and Bioelectronics (pp. 18-44). IGI Global. https://doi.org/10.4018/979-8-3693-2069-3.ch002

[13] Sudharshan, V.B. (2013). Human like biosensor disease simulator, disease analyzer and drug delivery system. In 2013 IEEE Conference on Information and Communication Technologies, ICT 2013 (pp. 1033–1038).